# Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

> **NCT03153358** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer Stage IV

## Interventions

- **DRUG:** Icotinib
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT03153358
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-02
- **Primary completion:** 2017-11-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153358, "Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03153358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*